Radius Health ticking higher in early trade amid renewed, vague takeover chatter out of the UK, mentioning Shire
FT Artcile :
'..Shire edged 0.6 per cent lower to £50.75 amid continued speculation around Radius Health, a US-listed osteoporosis drugmaker with a market value of $2.2bn.
Radius was rumoured to have recently rejected a bid of about $70 a share from Shire, a premium of 37 per cent on Wednesday’s price, with Shire said to be weighing up whether to sweeten the offer by about $10 a share.
Roche, Pfizer and Amgen have also been linked with Radius, which has key trial data due next month.